This special issue will describe cutting-edge translational research on the development of safe and effective therapeutics for treating exposure to toxic chemical threat agents that target the nervous system. These studies are supported by the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program. Chemical threats include chemical warfare agents, pesticides and other toxic chemicals whose primary mode of action is targeted within the nervous system. Depending on the dose, the effects of these toxic chemicals can be lethal or cause serious morbidity including neuropathology and neurological deficits. Current topics in research on organophosphorus pesticides and chemical warfare agents include developing alternatives to currently approve acetylcholinesterase reactivators, control of seizures that are refractory to benzodiazepine drugs, and treatments for serious morbidity caused by non-lethal exposures. There is also an effort to understand the mechanisms of toxicity and treatments for other neuro-active agents such as tetramine and hydrogen sulfide. A robust translational research effort on nerve agents is essential for being better prepared with an effective medical response capability during chemical emergencies.
Introduction
Chemical Nerve Agents (CNAs) have become of more and more concern because of their recent use in terrorism, warfare, and individual poisonings. These toxic chemicals are difficult to manage because of their rapid modes of action that can cause death within minutes, depending on the level of exposure and how quickly effective medical intervention can occur. Because of their rapid mode of target engagement and activation (or inhibition), medical interventions are often too late because of the time required to respond to remote sites and treat patients safely either in the field or in hospital emergency departments. This presents a substantial challenge to researchers developing safe and effective medical countermeasures (MCMs) because the candidate drug must be effective in reducing mortality and/or morbidity when it is administered, even if this is delayed for several minutes or hours.
Another challenge faced by researchers is that MCMs developed must have a concept of operation that is clearly relevant to chemical emergencies with potential mass causalities. The route of administration of the intended drug must also be consistent with a mass casualty event. For example, drugs that are only effective when administered intravenously may not be ideal for the pre-hospital setting since many patients would need to be treated at once. In some cases, drugs may be given in-hospital to prevent long-term effects after acute exposures. MCM researchers also aspire to develop drugs that are effective for a diverse demographic. In many cases of chemical releases involving the civilian population, special medical needs are required for people who are particularly vulnerable, including the young, the elderly, and individuals with pre-existing medical conditions. Pregnant women, infants and children are particularly vulnerable to the effects of chemical agents. These and other considerations are important for wholistic approaches to MCMs development.
This introductory article will provide some background information on CNA research and will be followed by several articles in this issue describing current research supported by the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) program which supports the development of safe and effective MCMs to reduce mortality and morbidity of chemical warfare agents and seizurogenic pesticides and other chemical threats.
Chemical threats to the nervous system
The civilian chemical threat spectrum includes chemical warfare agents (e.g., sarin, chlorine, sulfur mustard), toxic industrial chemicals (e.g., cyanide, hydrogen sulfide), pesticides (e.g., parathion, brodifacoum), pharmaceutical-based agents (e.g., opioids) and other https://doi.org/10.1016/j.nbd.2018.11.020 Received 16 November 2018; Accepted 19 November 2018 chemicals. These highly toxic chemicals could be deployed in a terrorist attack, released in a natural disaster or in large-scale industrial accidents in production, storage or shipping. Chemical agents are determined to be a threat to national security by the Department of Homeland Security (DHS). The list of chemical threats is quite large and antidotes that are specific to a single chemical are being developed, however, research is also being conducted on acute effects and pathologies that are common to several chemical threat agents, so that the therapeutics being developed will have a broader spectrum of activity against more than one chemical, i.e., efficacious against more than one chemical threat.
Many of these chemicals target the nervous system, including nerve agents such as sarin and VX, as well as organophosphorus (OP) pesticides like the phorate and chlorpyrifos, and the GABA agent tetramine (Table 1) . Most of the chemicals that target the nervous system are highly toxic and effective at low doses. Most of the chemicals target acetylcholinesterase (AChE), but some are GABA agents (Table 1) . Other chemical threats cause neurological effects, but these effects are not the primary cause for acute lethality.
Lethal and non-lethal acute effects
The toxicity of organophosphorus (OP) CNAs has been studied extensively in occupational and non-occupational settings. The clinical features and severity of poisoning largely depend on the toxicological properties of CNA, route of exposure, and delay in receiving adequate therapy (Pope and Brimijoin, 2018; Voorhees et al., 2016) . In fatal cases of intoxications, death occurs due to respiratory failure created by the combination of increased bronchial secretion, paralysis of peripheral respiratory muscles, and central apnea (Hulse et al., 2014; Vanova et al., 2018) . The underlying mechanism for these effects is the inhibition of AChE and subsequent rise in acetylcholine at cholinergic synapses in the peripheral and central nervous systems (Fig. 1) . This results in overstimulation of cholinergic receptors at critical synapse in the central and peripheral nervous systems, and the ultimate failure of respiratory function.
The most common non-lethal acute effect of OP CNAs are seizures caused by central nervous system hyperstimulation. This often progresses to status epilepticus (SE) which may lead to neuropathology and functional deficits in surviving victims. Seizures usually occur if the dose is lethal, but they are not the cause of death. The overstimulation of postsynaptic muscarinic acetylcholine receptors triggers epileptiform activity and activation of glutamate receptors, both of which cause a rise in intracellular calcium, other physiological and metabolic effects, and ultimately neuropathological changes (Fig. 1) . Chronic neuropathological sequelae may result from acute OP poisoning, due to the initiation of neurodegenerative processes driven by excitotoxic and neuroinflammatory responses.
Current medical countermeasures for nerve agents
Acute poisonings with OP CNAs are treated with atropine sulfate to inhibit peripheral and central muscarinic effects, and pralidoxime (2-PAM) chloride to reactivate inhibited AChE (Table 2) . Atropine blocks muscarinic cholinergic receptors in the parasympathetic nervous system to reduce excessive secretions and smooth muscle contraction. It does not have a significant therapeutic effect for central nervous system toxicity, nor does it appear to work well at cholinergic synapses on skeletal muscle. Other cholinergic drugs and drugs that interact with other neurotransmitter systems are under development that may be more selective and have fewer side effects. The oxime 2-PAM chloride appears to be most effective at nicotinic cholinergic synapses on skeletal muscle. It removes OP CNAs from the OP-AChE complex by virtue of its highly nucleophilic oxime moiety. However, once aging has occurred, the AChE is irreversibly inactivated and enzyme activity can only be restored by de novo re-synthesis. One of the biggest challenges with the use of 2-PAM is that it does not penetrate the blood-brain barrier very well, and its efficacy is controversial (Blumenberg et al., 2018) . There is a concerted effort to find better oxime (and other) AChE reactivators with broader spectrum activity (for several OP CNAs) and better central nervous system activity. Prolonged seizure activity after OP CNAs is controlled by the benzodiazepine anticonvulsant diazepam, or the recently FDA-approved similar drug, midazolam (Seizalam). Diazepam is an effective treatment for the seizures associated with nerve agent exposure, but it has limited bioavailability (Leppik and Patel, 2015) when administered intramuscularly, and there is a loss in efficacy after prolonged seizure activity. As with most drugs that suppress central nervous system activity, the potential for over-sedation and respiratory depression exists with diazepam, especially in cases where patients may already be suffering from paralysis or hypoxia from the nerve agent. This last point regarding OP-induced paralysis is also important when considering the diagnosis of seizure activity and appropriate treatments. The muscular effects of OP nerve agents may mask or mimic signs of seizure activity. Similar effects including seizures and SE are observed with other CNAs unrelated to OPs. Research is progressing on testing known anticonvulsants and neuroprotectants on the GABA agent tetramine which can also be controlled by benzodiazepines such as diazepam (Zolkowska et al., 2018) .
Long-term effects
Given the heterogeneity in the level of CNA exposures during a mass casualty event, some individuals may be exposed to non-lethal doses and experience serious nonlethal longer-term pathological sequelae that may occur days, weeks, or years later. This serious morbidity is likely caused by seizures and hypoxia which lead to neuronal damage, which can occur within minutes to days. Neuropathology could be linked to functional deficits seen days, months, or years later (Fig. 2) . Data supporting the link between exposure and neuropathology is much stronger than the link between neuropathology and lasting functional deficits. For example, multiple reports show that victims who were exposed to sarin in the Matsumoto and Tokyo subway attacks may have suffered long-term neurological effects, including behavioral abnormalities and alteration of brain morphology (Murata et al., 1997; Yamasue et al., 2007a; Yanagisawa et al., 2006) , but some of these effects may have multiple etiologies. Some of the deficits reported in humans include extended depression of circulating AChE activity (Baker and Sedgwick, 1996; Tochigi et al., 2002) , visual and ocular effects (Ohtani et al., 2004; Okumura et al., 2005) , learning, memory (Kawana et al., 2001; Miyaki et al., 2005) , and morphological and histopathology changes (Loh et al., 2010; Yamasue et al., 2007b) . Most of the above morbidities are consistent with those reported in animal studies on the effects of OP CNAs (Abu-Qare and Abou-Donia, 2002).
Current research has been focused on better therapeutics that would prevent the neuropathology and functional deficits associated with nonlethal effects of CNAs.
Animal models used for studying long-term effects should be based on the best available data from human exposures. This is a challenge since there is a paucity of data available because of the infrequency of chemical emergencies involving acute exposures only. Another challenge in developing animal models is the steep dose-response relationship for many of the most important chemical threats. For example, the nerve agent VX is lethal to 100% of guinea pigs after 24 h at a dose of 0.2 mg/kg, but VX does not cause any mortality at a dose of 0.1 mg/kg (unpublished data). This is mostly a problem when trying to develop animal models that exhibit the desired toxicity but survive that toxicity long enough to test a potential therapeutic. Fortunately, several drugs may be appropriate for re-purposing, such as neuroprotectants being developed to treat patients after stroke, status epilepticus, and other brain injuries.
The NIH CounterACT Program and Progress on Medical Countermeasures
The NIH chemical defense effort serves the nation providing funding, contract resources, and expertise to the scientific community to facilitate the discovery and development of civilian chemical MCMs. The NIH CounterACT Program provides grant resources, and there are contract facilities to support NIH CounterACT projects, and Interagency Agreements with the US Army Medical Research Institute of Chemical Defense (MRICD) to leverage the DoD experience with military MCM development. The overall goals of the NIH CounterACT Program are to: 1) develop MCM products that are ready for advanced development by other agencies, and 2) provide a fundamental science and technology knowledge base for the chemicals identified as a threat to the nation. This is a trans-NIH effort involving partnerships with several NIH Institutes that provide specific expertise, including the National Eye Institute, National Institute for Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke, National Library of Medicine, and other important resources at NIH.
The program manages a large portfolio of MCM projects. The scope of research supported by this program is an extensive range of basic, translational and preclinical research from confirmation of molecular targets for therapeutic development through non-GLP toxicity and pharmacology preclinical studies. Since its inception in 2006, the NIH CounterACT program has recruited into the MCM field over 100 of the nation's top laboratories, as well as senior investigators with a diverse area of expertise including epilepsy, lung disease, toxicology, wound healing, ophthalmology, pharmacology and pharmaceutics, genomics, emergency medicine, and protein engineering. The cutting-edge research generated by these scientists has resulted in many patents and over 1200 publications in high impact peer-reviewed journals that have provided an unprecedented enrichment in the scientific knowledge base for chemical threats agents. 
Conclusions
Exposure to chemical nerve agents after intentional or accidental release is often fatal due to their high toxicity and rapid mode of action. Translational research on CNAs is has produced a more effective anticonvulsant (midazolam) but there remain several research gaps. These include the need for better treatments for refractory seizures, greater control of cholinergic receptor hyperstimulation in the brain, better reactivation of inhibited AChE, and prevention of long-term serious morbidity after non-lethal exposures. The NIH CounterACT program supports a diverse portfolio of cutting-edge research to address these research needs.
